Anticancer Drugs Oncology Pharmacology Physiotherapy Ripretinib

Ripretinib (Mechanism of Action)

In this article we will discuss Ripretinib (Mechanism of Action)

In this article, we will discuss Ripretinib (Mechanism of Action). So, let’s get started.

Mechanism of Action

Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, and secondary mutations. Ripretinib also inhibits other kinases in vitro, such as PDGFRB, TIE2, VEGFR2, and BRAF.


Exposure-Response Relationships
Ripretinib exposure-response relationships and the time course of pharmacodynamics have not been fully characterized.

Cardiac Electrophysiology

No large mean increase in QTc interval (i.e. >20 ms) was detected following treatment with Ripretinib at the recommended dose of 150 mg taken orally once daily.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.